Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (981-990 of 1,060) with videos related to

Pageof 106
Sort By:
Circulation|November 9, 2005
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failureMarvin A Konstam, Barbara Czerska, Michael Böhm, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JAMA Cardiology|January 30, 2020
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart FailureJoanne Simpson, Pardeep S Jhund, Lars H Lund, et al.
Pageof 106

Showing results (981-990 of 1,060) with videos related to

Sort By:
Pageof 106
Circulation|November 9, 2005
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failureMarvin A Konstam, Barbara Czerska, Michael Böhm, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 1, 2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEFJonathan W Cunningham, Brian L Claggett, Eileen O'Meara, et al.
JACC. Heart Failure|May 11, 2020
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical TrialsJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|April 28, 2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialMaja Cikes, Ivo Planinc, Brian Claggett, et al.
JAMA Cardiology|January 30, 2020
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart FailureJoanne Simpson, Pardeep S Jhund, Lars H Lund, et al.
Pageof 106